The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CLIMATE: Assessing the clinical utility of miR-371a-3p as a marker of residual disease in stage 1 testicular germ cell tumour (TGCT) following orchiectomy: ANZUP 1906.
 
Ciara Conduit
Honoraria - AstraZeneca
 
Peter S. Grimison
Research Funding - Daiichi Sankyo Europe GmbH (Inst); Daiichi Sankyo Europe GmbH (Inst); Eisai (Inst); Epizyme (Inst); Genentech (Inst); Janssen-Cilag (Inst); Medimmune; MSD (Inst); Pfizer (Inst); Pfizer (Inst); PTC Therapeutics (Inst); PTC Therapeutics (Inst); QED Therapeutics (Inst); Tilray (Inst)
 
Jeremy Howard Lewin
Consulting or Advisory Role - Bayer (Inst)
 
Aaron Richard Hansen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Neoleukin Therapeutics (Inst); Pfizer/EMD Serono (Inst); Roche/Genentech (Inst)
 
James F. Lynam
Employment - Precision for Medicine
Leadership - Healthscope Advanced Pathology
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Ipsen; Janssen
 
Andrew James Weickhardt
Honoraria - Eisai; Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer
Speakers' Bureau - Astellas Pharma
Research Funding - Merck
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Merck Sharp & Dohme
 
Phillip Parente
No Relationships to Disclose
 
David Colin Campbell
No Relationships to Disclose
 
Wei Hong
No Relationships to Disclose
 
Gavin M. Marx
No Relationships to Disclose
 
Orlaith Mary Heron
No Relationships to Disclose
 
Anna Kuchel
No Relationships to Disclose
 
Margaret Mary McJannett
No Relationships to Disclose
 
Thomas Cusick
No Relationships to Disclose
 
Antoinette Fontela
No Relationships to Disclose
 
Sophie O Haire
No Relationships to Disclose
 
Kristina Zlatic
No Relationships to Disclose
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Medivation (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
 
Ben Tran
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Janssen-Cilag; Pfizer; Sanofi; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; IQvia; Janssen-Cilag; MSD Oncology; Novartis; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche Molecular Diagnostics; Sanofi; Tolmar
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Ipsen; Janssen-Cilag (Inst); Merck Sharp & Dohme; Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma